Some safety aspects of a new russian pegylated interferon-A medication “ALGERON” (phase 1 clinical trial)
- Autores: Tukach AI1, Fitilev SB1, Shkrebniova II1, Vozzhaev AV1, Yakushev VA1, Ivanov RA2, Lin’kova Y.N2, Chernovskaya TV2
-
Afiliações:
- Peoples’ Friendship University of Russia
- «Biocad», Research and Development
- Edição: Nº 2 (2014)
- Páginas: 114-118
- Seção: Articles
- URL: https://journals.rcsi.science/2313-0245/article/view/337038
- ID: 337038
Citar
Texto integral
Resumo
Sobre autores
A Tukach
Peoples’ Friendship University of Russia
Email: fitilevsb@yandex.ru
Department of general and clinic pharmacology
S Fitilev
Peoples’ Friendship University of Russia
Email: fitilevsb@yandex.ru
Department of general and clinic pharmacology
I Shkrebniova
Peoples’ Friendship University of Russia
Email: fitilevsb@yandex.ru
Department of general and clinic pharmacology
A Vozzhaev
Peoples’ Friendship University of Russia
Email: fitilevsb@yandex.ru
Department of general and clinic pharmacology
V Yakushev
Peoples’ Friendship University of Russia
Email: fitilevsb@yandex.ru
Department of general and clinic pharmacology
R Ivanov
«Biocad», Research and Development
Email: fitilevsb@yandex.ru
Yu Lin’kova
«Biocad», Research and Development
Email: fitilevsb@yandex.ru
T Chernovskaya
«Biocad», Research and Development
Email: fitilevsb@yandex.ru
Arquivos suplementares
